ReviewJournal of experimental & clinical cancer research : CR2011
Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research.
Review in Journal of experimental & clinical cancer research : CR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review.Journal of experimental & clinical cancer research : CR · 2013Pooled it
- Can Molecular Biomarkers be Utilized to Determine Appropriate Adjuvant Therapy in Early-Stage Non-Small Cell Lung Cancer (NSCLC)?Journal of cellular immunology · 2024Article
- Prognostic score and sex-specific nomograms to predict survival in resectable lung cancer: A French nationwide study from the Epithor cohort database.The Lancet regional health. Europe · 2023Article
- A Pan-Cancer Analysis on the Systematic Correlation of MutS Homolog 2 (MSH2) to a Malignant Tumor.Journal of oncology · 2022Article
- Proportion of Patients in Phase I Oncology Trials Receiving Treatments That Are Ultimately Approved.Journal of the National Cancer Institute · 2020Article
- LACES and bootstraps: the hunt for prognostic and predictive markers for adjuvant therapy in NSCLC.Translational lung cancer research · 2018Article
- Can body composition be used to optimize the dose of platinum chemotherapy in lung cancer? A feasibility study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2017Article
- Knockdown of ANXA1 suppresses the biological behavior of human NSCLC cells in vitro.Molecular medicine reports · 2016Article
- Predominant histologic subtype in lung adenocarcinoma predicts benefit from adjuvant chemotherapy in completely resected patients: discovery of a holy grail?Annals of translational medicine · 2016Article
- DAL-1 attenuates epithelial-to mesenchymal transition in lung cancer.Journal of experimental & clinical cancer research : CR · 2015Article
- Clinical significance of Girdin expression detected by immunohistochemistry in non-small cell lung cancer.Oncology letters · 2014Article
- Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].PloS one · 2014Article
- Adjuvant chemotherapy and radiotherapy in the treatment of non-small cell lung cancer (NSCLC).Journal of thoracic disease · 2013Review
- Neoadjuvant EGFR TKIs: toward personalized management in non-small-cell lung cancer.Translational lung cancer research · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adjuvant chemotherapy for non-small-cell lung carcinoma (NSCLC) is a debated issue in clinical oncology. Although it is considered a standard for resected stage II-IIIA patients according to the available guidelines, many questions are still open. Among them, it should be acknowledged that the treatment for stage IB disease has shown so far a limited (if sizable) efficacy, the role of modern radiotherapies requires to be evaluated in large prospective randomized trials and the relative impact of age and comorbidities should be weighted to assess the reliability of the trials' evidences in the context of the everyday-practice. In addition, a conclusive evidence of the best partner for cisplatin is currently awaited as well as a deeper investigation of the fading effect of chemotherapy over time. The limited survival benefit since first studies were published and the lack of reliable prognostic and predictive factors beyond pathological stage, strongly call for the identification of bio-molecular markers and classifiers to identify which patients should be treated and which drugs should be used. Given the disappointing results of targeted therapy in this setting have obscured the initial promising perspectives, a biomarker-selection approach may represent the basis of future trials exploring adjuvant treatment for resected NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.